Shares of Ophthotech Corp (NASDAQ:OPHT) have earned an average recommendation of “Buy” from the four research firms that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $3.63.
A number of equities research analysts recently weighed in on OPHT shares. Zacks Investment Research raised Ophthotech from a “hold” rating to a “strong-buy” rating and set a $3.25 price target for the company in a report on Monday, November 13th. ValuEngine raised Ophthotech from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Finally, TheStreet raised Ophthotech from an “e+” rating to a “c” rating in a report on Thursday, November 30th.
In other news, insider David R. Guyer sold 16,520 shares of Ophthotech stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $3.19, for a total value of $52,698.80. Following the completion of the sale, the insider now directly owns 50,494 shares of the company’s stock, valued at approximately $161,075.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Glenn Sblendorio sold 8,089 shares of Ophthotech stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $3.19, for a total value of $25,803.91. Following the completion of the sale, the chief executive officer now directly owns 44,584 shares of the company’s stock, valued at $142,222.96. The disclosure for this sale can be found here. Insiders have sold a total of 34,971 shares of company stock valued at $111,481 over the last ninety days. Insiders own 2.00% of the company’s stock.
Ophthotech (NASDAQ OPHT) remained flat at $$2.94 during mid-day trading on Friday. 260,651 shares of the company’s stock were exchanged, compared to its average volume of 354,770. Ophthotech has a fifty-two week low of $2.24 and a fifty-two week high of $4.86. The stock has a market capitalization of $105.95, a price-to-earnings ratio of 1.87 and a beta of 1.58.
Ophthotech (NASDAQ:OPHT) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $5.25 earnings per share for the quarter, beating the Zacks’ consensus estimate of $4.38 by $0.87. Ophthotech had a negative return on equity of 69.40% and a net margin of 26.69%. analysts anticipate that Ophthotech will post 2.88 earnings per share for the current year.
Ophthotech Company Profile
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.
Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.